Apretude ViiV Healthcare | Cabotegravir (PrEP) | INSTI (Long-Acting PrEP) | Reimbursed | Reimbursed at 100% by national health insurance under a ministerial order of 18 February 2026, published in the Journal officiel on 26 February 2026 and effective from 2 March 2026 (price EUR 1,312.07 per injection). HAS opinion of 29 May 2024: SMR important, ASMR IV. [Sources: https://base-donnees-publique.medicaments.gouv.fr/medicament/62595850/extrait ; https://www.service-public.gouv.fr/particuliers/actualites/A18853?lang=en ; https://www.lemoniteurdespharmacies.fr/therapeutique/medicaments/fiches-medicaments/apretude-une-nouvelle-ere-pour-la-prep-en-france] | 02/11/2026 |
Biktarvy Gilead Sciences | Bictegravir / Emtricitabine / TAF | INSTI + NRTI/NtRTI | Reimbursed | 100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS] | 14/09/2026 |
Celsentri ViiV Healthcare | Maraviroc | Entry Inhibitor | Reimbursed | 100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS] | 14/09/2026 |
Delstrigo Merck | Doravirine / Lamivudine / Tenofovir DF | NNRTI + NRTI/NtRTI | Reimbursed | 100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS] | 14/09/2026 |
Descovy Gilead Sciences | Emtricitabine / TAF | NRTI | Reimbursed | 100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS] | 14/09/2026 |
Dovato ViiV Healthcare | Dolutegravir / Lamivudine | INSTI + NRTI | Reimbursed | 100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS] | 14/09/2026 |
Edurant Janssen | Rilpivirine | NNRTI | Reimbursed | 100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS] | 14/09/2026 |
Emtriva Gilead Sciences | Emtricitabine | NRTI | Reimbursed | Listed in the French public medicines database as reimbursed at 100% by national health insurance. Initial prescription is reserved for hospital doctors (annual). Checked 2 November 2026. [Source: https://base-donnees-publique.medicaments.gouv.fr/medicament/61294762/extrait] | 02/11/2026 |
Epivir ViiV Healthcare | Lamivudine | NRTI | Reimbursed | Listed in the French public medicines database as reimbursed at 100% by national health insurance. Initial prescription is reserved for hospital doctors (annual). Checked 2 November 2026. [Source: https://base-donnees-publique.medicaments.gouv.fr/medicament/64777862/extrait] | 02/11/2026 |
Eviplera Gilead Sciences | Rilpivirine / Emtricitabine / Tenofovir DF | NNRTI + NRTI/NtRTI | Reimbursed | Listed in the French public medicines database as reimbursed at 100% by national health insurance. Initial prescription is reserved for hospital doctors (annual). Checked 2 November 2026. [Source: https://base-donnees-publique.medicaments.gouv.fr/medicament/63578537/extrait] | 02/11/2026 |
Generic TDF/FTC (Emtricitabine/Tenofovir DF) Multiple (Generics) | Emtricitabine / Tenofovir DF | NRTI | Reimbursed | Fully financed through the national health insurance framework. [Source: Santé publique France / HAS] | 14/09/2026 |
Genvoya Gilead Sciences | Elvitegravir / Cobicistat / Emtricitabine / TAF | INSTI + NRTI/NtRTI + pharmacokinetic enhancer | Reimbursed | 100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS] | 14/09/2026 |
Intelence Janssen | Etravirine | NNRTI | Reimbursed | 100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS] | 14/09/2026 |
Isentress Merck | Raltegravir | INSTI | Reimbursed | 100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS] | 14/09/2026 |
Juluca ViiV Healthcare | Dolutegravir / Rilpivirine | INSTI + NNRTI | Reimbursed | 100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS] | 14/09/2026 |
Kaletra AbbVie | Lopinavir / Ritonavir | PI | Reimbursed | 100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS] | 14/09/2026 |
Kivexa ViiV Healthcare | Abacavir / Lamivudine | NRTI | Reimbursed | Listed in the French public medicines database as reimbursed at 100% by national health insurance. Initial prescription is reserved for hospital doctors (annual); renewal is unrestricted. Checked 2 November 2026. [Source: https://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=69855489] | 02/11/2026 |
Norvir AbbVie | Ritonavir | PI + pharmacokinetic enhancer | Reimbursed | Listed in the French public medicines database as reimbursed at 100% by national health insurance. Checked 2 November 2026. [Source: https://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=67851855] | 02/11/2026 |
Odefsey Gilead Sciences | Rilpivirine / Emtricitabine / TAF | NNRTI + NRTI/NtRTI | Reimbursed | 100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS] | 14/09/2026 |
Pifeltro Merck | Doravirine | NNRTI | Reimbursed | 100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS] | 14/09/2026 |
Prezista Janssen | Darunavir | PI | Reimbursed | 100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS] | 14/09/2026 |
Rekambys Janssen | Rilpivirine | Long-Acting NNRTI | Reimbursed | Long-acting injectable rilpivirine used with cabotegravir for maintenance treatment in eligible virologically suppressed patients. The existing France record for the complete Vocabria / Rekambys regimen is classified as 'Available and Reimbursed', so this required rilpivirine component uses the same access and reimbursement status. EU regulatory update (as of 5 Oct 2026): on 31 January 2025 the European Commission extended the authorisation of Vocabria plus Rekambys long-acting injections to virologically suppressed adolescents aged 12 years and older weighing at least 35 kg (adults authorised since December 2020). National reimbursement for adolescents not verified. [Sources: https://www.ema.europa.eu/en/medicines/human/EPAR/rekambys; https://www.pharmiweb.com/press-release/2025-01-31/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents-1; https://i-base.info/htb/50121] | 14/09/2026 |
Retrovir ViiV Healthcare | Zidovudine | NRTI | Reimbursed | Listed in the French public medicines database as reimbursed at 100% by national health insurance. Checked 2 November 2026. [Source: https://base-donnees-publique.medicaments.gouv.fr/medicament/63894243/extrait] | 02/11/2026 |
Reyataz Bristol Myers Squibb | Atazanavir | PI | Reimbursed | Listed in the French public medicines database as reimbursed at 100% by national health insurance. Initial prescription is reserved for hospital doctors (annual). Checked 2 November 2026. [Source: https://base-donnees-publique.medicaments.gouv.fr/medicament/66745660/extrait] | 02/11/2026 |
Rukobia ViiV Healthcare | Fostemsavir | Attachment Inhibitor | Reimbursed | 100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS] | 14/09/2026 |
Stribild Gilead Sciences | Elvitegravir / Cobicistat / Emtricitabine / Tenofovir DF | INSTI + NRTI/NtRTI + pharmacokinetic enhancer | Reimbursed | Listed in the French public medicines database as reimbursed at 100% by national health insurance. Reimbursed for treatment-naive adults; initial prescription is reserved for hospital doctors (annual). Checked 2 November 2026. [Source: https://base-donnees-publique.medicaments.gouv.fr/medicament/65768058/extrait] | 02/11/2026 |
Sunlenca Gilead Sciences | Lenacapavir | Capsid Inhibitor | Reimbursed | 100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS] | 14/09/2026 |
Symtuza Janssen | Darunavir / Cobicistat / Emtricitabine / TAF | PI + NRTI/NtRTI + pharmacokinetic enhancer | Reimbursed | 100% covered by the French social security system (ALD 7) for eligible patients. EU regulatory update (as of 5 Oct 2026): on 25 June 2026 the CHMP adopted a positive opinion extending the indication, with a new 675/150/200/10 mg tablet strength, to adults and paediatric patients aged 6 years and older weighing at least 25 kg (previously adolescents aged 12 years and older weighing at least 40 kg). European Commission decision not confirmed during this review; national availability and reimbursement of the new strength not verified. [Sources: Santé publique France / HAS; https://www.ema.europa.eu/en/medicines/human/variation/symtuza] | 14/09/2026 |
Tivicay ViiV Healthcare | Dolutegravir | INSTI | Reimbursed | 100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS] | 14/09/2026 |
Triumeq ViiV Healthcare | Dolutegravir / Abacavir / Lamivudine | INSTI + NRTI | Reimbursed | 100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS] | 14/09/2026 |
Truvada Gilead Sciences | Emtricitabine / Tenofovir DF | NRTI | Reimbursed | 100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS] | 14/09/2026 |
Viread Gilead Sciences | Tenofovir DF | NtRTI | Reimbursed | Listed in the French public medicines database as reimbursed at 100% by national health insurance. Initial prescription is reserved for hospital doctors (annual). Checked 2 November 2026. [Source: https://base-donnees-publique.medicaments.gouv.fr/medicament/67279692/extrait] | 02/11/2026 |
Vocabria ViiV Healthcare | Cabotegravir | INSTI | Reimbursed | 100% covered by the French social security system (ALD 7) for eligible patients. EU regulatory update (as of 5 Oct 2026): on 31 January 2025 the European Commission extended the authorisation of Vocabria plus Rekambys long-acting injections to virologically suppressed adolescents aged 12 years and older weighing at least 35 kg (adults authorised since December 2020). National reimbursement for adolescents not verified. [Sources: Santé publique France / HAS; https://www.pharmiweb.com/press-release/2025-01-31/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents-1; https://i-base.info/htb/50121] | 14/09/2026 |
Vocabria / Rekambys ViiV Healthcare / Janssen | Cabotegravir / Rilpivirine | Long-Acting ART | Reimbursed | EMA approved. Fully or partially reimbursed under the national health system for virologically suppressed patients. EU regulatory update (as of 5 Oct 2026): on 31 January 2025 the European Commission extended the authorisation of Vocabria plus Rekambys long-acting injections to virologically suppressed adolescents aged 12 years and older weighing at least 35 kg (adults authorised since December 2020). National reimbursement for adolescents not verified. [Sources: Santé publique France / HAS; https://www.pharmiweb.com/press-release/2025-01-31/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents-1; https://i-base.info/htb/50121] | 02/11/2026 |
Ziagen ViiV Healthcare | Abacavir | NRTI | Reimbursed | Listed in the French public medicines database as reimbursed at 100% by national health insurance. Initial prescription is reserved for hospital doctors (annual). Checked 2 November 2026. [Source: https://base-donnees-publique.medicaments.gouv.fr/medicament/68556562/extrait] | 02/11/2026 |
Generic TLD (Tenofovir/Lamivudine/Dolutegravir) Multiple (Generics) | Tenofovir DF / Lamivudine / Dolutegravir | INSTI + NRTI/NtRTI | Not available | Generic combinations are typically not procured as branded single-tablet regimens are widely available. [Source: Santé publique France / HAS] | 14/09/2026 |
Generic TLE (Tenofovir/Lamivudine/Efavirenz) Multiple (Generics) | Tenofovir DF / Lamivudine / Efavirenz | NNRTI + NRTI/NtRTI | Not available | Generic combinations are typically not procured as branded single-tablet regimens are widely available. [Source: Santé publique France / HAS] | 14/09/2026 |
Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris Viatris Limited | Emtricitabine / Rilpivirine / Tenofovir alafenamide | NNRTI + NRTI/NtRTI | Under review | EMA confirms an EU/EEA-wide marketing authorisation issued on 19 August 2025. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris] | 14/09/2026 |
Emtricitabine / Tenofovir alafenamide Viatris Viatris Limited | Emtricitabine / Tenofovir alafenamide | NRTI/NtRTI | Under review | EMA confirms an EU/EEA-wide marketing authorisation issued on 18 July 2025. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-tenofovir-alafenamide-viatris] | 14/09/2026 |
Evotaz Bristol Myers Squibb | Atazanavir / Cobicistat | PI + pharmacokinetic enhancer | Under review | EMA confirms an EU/EEA-wide marketing authorisation issued on 13 July 2015. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/evotaz] | 14/09/2026 |
Rezolsta Janssen | Darunavir / Cobicistat | PI + pharmacokinetic enhancer | Under review | A fixed-dose combination of darunavir and cobicistat used with other antiretrovirals. EMA's CHMP issued a positive opinion on 25 June 2026 for a dispersible formulation and paediatric use from age 3 years and 15 kg. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta] | 14/09/2026 |
Yeytuo Gilead Sciences | Lenacapavir (PrEP) | Capsid Inhibitor (Long-Acting PrEP) | Under review | Twice-yearly injectable lenacapavir for pre-exposure prophylaxis; a separate marketing authorisation from Sunlenca, which covers treatment. The European Commission granted an EU/EEA-wide marketing authorisation on 26 August 2025 following accelerated EMA assessment. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/yeytuo] | 14/09/2026 |